Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein ExpressionAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorderRecruitingPhase 32026-08-12NCT07546500

3 results · Page 1 of 1

59 results · Page 1 of 3

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Site 0101TorranceUnited States1
Site 0104Beverly HillsUnited States1
Site 0105PortlandUnited States1
Site 0107PhoenixUnited States1
Site 0108ColumbusUnited States1
Site 0109PhiladelphiaUnited States1
Site 0110AntiochUnited States1
Site 0111CamdenUnited States1
Site 0112Sioux FallsUnited States1
Site 0113PhiladelphiaUnited States1
Site 0114Willow GroveUnited States1
Site 0115San FranciscoUnited States1
Site 0201TorontoCanada1
Site 0202SherbrookeCanada1
Site 0203MontrealCanada1
Site 0204MontrealCanada1
Site 1101RandwickAustralia1
Site 1102AdelaideAustralia1
Site 1103NedlandsAustralia1
Site 1201SeoulSouth Korea1
Site 1202SeoulSouth Korea1
Site 1203DaeguSouth Korea1
Site 1204SeoulSouth Korea1
Site 1205SeoulSouth Korea1
Site 1206Goyang-siSouth Korea1